+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12326(MED14 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of MED14 Antibody**

The MED14 antibody targets the MED14 protein, a critical subunit of the Mediator complex—a multi-protein assembly essential for regulating RNA polymerase II (Pol II)-mediated transcription in eukaryotes. The Mediator complex acts as a molecular bridge, facilitating communication between transcription factors (TFs) and the basal transcriptional machinery. MED14. encoded by the *MED14* gene, plays a pivotal role in stabilizing the Mediator’s architecture and coordinating its interactions with Pol II and TFs.

MED14 is implicated in diverse cellular processes, including cell cycle regulation, differentiation, and stress responses. Dysregulation of MED14 has been linked to diseases such as cancer, neurodevelopmental disorders, and cardiovascular conditions. For instance, aberrant MED14 expression can disrupt transcriptional programs that drive tumor progression or impair cellular homeostasis.

Antibodies against MED14 are widely used in research to investigate Mediator complex dynamics, chromatin interactions (e.g., ChIP-seq), and protein localization (e.g., immunofluorescence). They also aid in studying MED14’s role in disease mechanisms or drug responses. Validated MED14 antibodies are essential for ensuring specificity in experiments, given the structural complexity of the Mediator and potential cross-reactivity with other subunits. Recent studies further explore MED14 as a potential therapeutic target, emphasizing the antibody’s utility in both basic and translational research contexts.